1. |
Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
|
2. |
Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol, 2016, 11(1): 39-51.
|
3. |
Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol, 2010, 28(1): 35-42.
|
4. |
Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage ⅠB-ⅢA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol, 2006, 7(9): 719-727.
|
5. |
Pepe C, Hasan B, Winton TL, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol, 2007, 25(12): 1553-1561.
|
6. |
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. Version 2.2019. 2018, 2019(2019.1.4).
|
7. |
Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol, 2008, 26(21): 3552-3559.
|
8. |
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 2011, 331(6024): 1565-1570.
|
9. |
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med, 2015, 373(2): 123-135.
|
10. |
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med, 2015, 373(17): 1627-1639.
|
11. |
Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med, 2016, 375(19): 1823-1833.
|
12. |
Hellmann MD, Chaft JE, William WJ, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol, 2014, 15(1): e42-e50.
|
13. |
Blumenthal GM, Bunn PJ, Chaft JE, et al. Current status and future perspectives on neoadjuvant therapy in lung cancer. J Thorac Oncol, 2018, 13(12): 1818-1831.
|
14. |
Li N, Ying J, Tao X, et al. Efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable squamous non-small cell lung cancer (sqNSCLC). J Thorac Oncol, 2019, 37(15_suppl): 8531.
|
15. |
Bar J, Urban D, Ofek E, et al. Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Updated report of a phase Ⅰ study, MK3475-223. J Clin Oncol, 2019, 37(15_suppl): 8534-8534.
|
16. |
Shu CA, Grigg C, Chiuzan C, et al. Neoadjuvant atezolizumab + chemotherapy in resectable non-small cell lung cancer (NSCLC). J Clin Oncol, 2018, 36(15_suppl): 8532-8532.
|
17. |
Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. J Clin Oncol, 2019, 37(15_suppl): 8504.
|
18. |
Kwiatkowski DJ, Rusch VW, Chaft JE, et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3). J Clin Oncol, 2019, 37(15_suppl): 8503.
|
19. |
Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemo-immunotherapy for the treatment of stage ⅢA resectable non-small-cell lung cancer (NSCLC): A phaseⅡ multicenter exploratory study—Final data of patients who underwent surgical assessment. J Clin Oncol, 2019, 37(15_suppl): 8509.
|
20. |
Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 nlockade in resectable lung cancer. N Engl J Med, 2018, 378(21): 1976-1986.
|
21. |
Bott MJ, Yang SC, Park BJ, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg, 2019, 158(1): 269-276.
|
22. |
Sepesi B, Cascone T, William W, et al. OA13.06 surgical outcomes following neoadjuvant nivolumab or nivolumab plus ipilimumab in non-small cell lung cancer - NEOSTAR Study. J Thorac Oncol, 2019, 14(10): S241-S242.
|